Global Peptide CDMO Services Supply, Demand and Key Producers, 2023-2029

Description

The global Peptide CDMO Services market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Peptide CDMO services usually cover the following aspects: peptide synthesis, process development, quality control, scale production, injection preparation. By choosing peptide CDMO services, the development and manufacture of peptide drugs can be handed over to professional institutions, thereby saving time, reducing costs, and ensuring product quality and compliance.

Peptide CDMO services refer to peptide drug development and manufacturing outsourcing services. Polypeptides are short-chain proteins composed of amino acids and have a wide range of biological activities and pharmacological applications.

This report studies the global Peptide CDMO Services demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Peptide CDMO Services, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide CDMO Services that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Peptide CDMO Services total market, 2018-2029, (USD Million)
Global Peptide CDMO Services total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Peptide CDMO Services total market, key domestic companies and share, (USD Million)
Global Peptide CDMO Services revenue by player and market share 2018-2023, (USD Million)
Global Peptide CDMO Services total market by Type, CAGR, 2018-2029, (USD Million)
Global Peptide CDMO Services total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Peptide CDMO Services market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Incyte, Gliead, Boehringer Ingelheim, Vertex, Mirati Therapeutics, AMPAC, Pfizer, Polypeptide and Bachem, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Peptide CDMO Services market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Peptide CDMO Services Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Peptide CDMO Services Market, Segmentation by Type
    Small Molecule CDMO
    Macro-molecular CDMO

Global Peptide CDMO Services Market, Segmentation by Application
    Clinical Treatment
    Medical Research
    Commercial Production

Companies Profiled:
    Incyte
    Gliead
    Boehringer Ingelheim
    Vertex
    Mirati Therapeutics
    AMPAC
    Pfizer
    Polypeptide
    Bachem
    Merck
    Asymchem
    Zhejiang Jiuzhou Pharmaceutical
    Sinopep
    Frontier Biotechnologies
    JYMed
    Chengdu Shengnuo Biotechnology
    Shanghai Soho-Yiming Pharmaceuticals
    Chinese Peptide Company
    Ambio Pharmaceuticals
    Zhejiang Peptites Biotech
    STA Pharmaceutical

Key Questions Answered
1. How big is the global Peptide CDMO Services market?
2. What is the demand of the global Peptide CDMO Services market?
3. What is the year over year growth of the global Peptide CDMO Services market?
4. What is the total value of the global Peptide CDMO Services market?
5. Who are the major players in the global Peptide CDMO Services market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Peptide CDMO Services Introduction
    1.2 World Peptide CDMO Services Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Peptide CDMO Services Total Market by Region (by Headquarter Location)
        1.3.1 World Peptide CDMO Services Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Peptide CDMO Services Market Size (2018-2029)
        1.3.3 China Peptide CDMO Services Market Size (2018-2029)
        1.3.4 Europe Peptide CDMO Services Market Size (2018-2029)
        1.3.5 Japan Peptide CDMO Services Market Size (2018-2029)
        1.3.6 South Korea Peptide CDMO Services Market Size (2018-2029)
        1.3.7 ASEAN Peptide CDMO Services Market Size (2018-2029)
        1.3.8 India Peptide CDMO Services Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Peptide CDMO Services Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Peptide CDMO Services Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Peptide CDMO Services Consumption Value (2018-2029)
    2.2 World Peptide CDMO Services Consumption Value by Region
        2.2.1 World Peptide CDMO Services Consumption Value by Region (2018-2023)
        2.2.2 World Peptide CDMO Services Consumption Value Forecast by Region (2024-2029)
    2.3 United States Peptide CDMO Services Consumption Value (2018-2029)
    2.4 China Peptide CDMO Services Consumption Value (2018-2029)
    2.5 Europe Peptide CDMO Services Consumption Value (2018-2029)
    2.6 Japan Peptide CDMO Services Consumption Value (2018-2029)
    2.7 South Korea Peptide CDMO Services Consumption Value (2018-2029)
    2.8 ASEAN Peptide CDMO Services Consumption Value (2018-2029)
    2.9 India Peptide CDMO Services Consumption Value (2018-2029)

3 World Peptide CDMO Services Companies Competitive Analysis
    3.1 World Peptide CDMO Services Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Peptide CDMO Services Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Peptide CDMO Services in 2022
        3.2.3 Global Concentration Ratios (CR8) for Peptide CDMO Services in 2022
    3.3 Peptide CDMO Services Company Evaluation Quadrant
    3.4 Peptide CDMO Services Market: Overall Company Footprint Analysis
        3.4.1 Peptide CDMO Services Market: Region Footprint
        3.4.2 Peptide CDMO Services Market: Company Product Type Footprint
        3.4.3 Peptide CDMO Services Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Peptide CDMO Services Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Peptide CDMO Services Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Peptide CDMO Services Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Peptide CDMO Services Consumption Value Comparison
        4.2.1 United States VS China: Peptide CDMO Services Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Peptide CDMO Services Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Peptide CDMO Services Companies and Market Share, 2018-2023
        4.3.1 United States Based Peptide CDMO Services Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Peptide CDMO Services Revenue, (2018-2023)
    4.4 China Based Companies Peptide CDMO Services Revenue and Market Share, 2018-2023
        4.4.1 China Based Peptide CDMO Services Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Peptide CDMO Services Revenue, (2018-2023)
    4.5 Rest of World Based Peptide CDMO Services Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Peptide CDMO Services Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Peptide CDMO Services Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Peptide CDMO Services Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Small Molecule CDMO
        5.2.2 Macro-molecular CDMO
    5.3 Market Segment by Type
        5.3.1 World Peptide CDMO Services Market Size by Type (2018-2023)
        5.3.2 World Peptide CDMO Services Market Size by Type (2024-2029)
        5.3.3 World Peptide CDMO Services Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Peptide CDMO Services Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Clinical Treatment
        6.2.2 Medical Research
        6.2.3 Commercial Production
    6.3 Market Segment by Application
        6.3.1 World Peptide CDMO Services Market Size by Application (2018-2023)
        6.3.2 World Peptide CDMO Services Market Size by Application (2024-2029)
        6.3.3 World Peptide CDMO Services Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Incyte
        7.1.1 Incyte Details
        7.1.2 Incyte Major Business
        7.1.3 Incyte Peptide CDMO Services Product and Services
        7.1.4 Incyte Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Incyte Recent Developments/Updates
        7.1.6 Incyte Competitive Strengths & Weaknesses
    7.2 Gliead
        7.2.1 Gliead Details
        7.2.2 Gliead Major Business
        7.2.3 Gliead Peptide CDMO Services Product and Services
        7.2.4 Gliead Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Gliead Recent Developments/Updates
        7.2.6 Gliead Competitive Strengths & Weaknesses
    7.3 Boehringer Ingelheim
        7.3.1 Boehringer Ingelheim Details
        7.3.2 Boehringer Ingelheim Major Business
        7.3.3 Boehringer Ingelheim Peptide CDMO Services Product and Services
        7.3.4 Boehringer Ingelheim Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Boehringer Ingelheim Recent Developments/Updates
        7.3.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
    7.4 Vertex
        7.4.1 Vertex Details
        7.4.2 Vertex Major Business
        7.4.3 Vertex Peptide CDMO Services Product and Services
        7.4.4 Vertex Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Vertex Recent Developments/Updates
        7.4.6 Vertex Competitive Strengths & Weaknesses
    7.5 Mirati Therapeutics
        7.5.1 Mirati Therapeutics Details
        7.5.2 Mirati Therapeutics Major Business
        7.5.3 Mirati Therapeutics Peptide CDMO Services Product and Services
        7.5.4 Mirati Therapeutics Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Mirati Therapeutics Recent Developments/Updates
        7.5.6 Mirati Therapeutics Competitive Strengths & Weaknesses
    7.6 AMPAC
        7.6.1 AMPAC Details
        7.6.2 AMPAC Major Business
        7.6.3 AMPAC Peptide CDMO Services Product and Services
        7.6.4 AMPAC Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 AMPAC Recent Developments/Updates
        7.6.6 AMPAC Competitive Strengths & Weaknesses
    7.7 Pfizer
        7.7.1 Pfizer Details
        7.7.2 Pfizer Major Business
        7.7.3 Pfizer Peptide CDMO Services Product and Services
        7.7.4 Pfizer Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 Pfizer Recent Developments/Updates
        7.7.6 Pfizer Competitive Strengths & Weaknesses
    7.8 Polypeptide
        7.8.1 Polypeptide Details
        7.8.2 Polypeptide Major Business
        7.8.3 Polypeptide Peptide CDMO Services Product and Services
        7.8.4 Polypeptide Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Polypeptide Recent Developments/Updates
        7.8.6 Polypeptide Competitive Strengths & Weaknesses
    7.9 Bachem
        7.9.1 Bachem Details
        7.9.2 Bachem Major Business
        7.9.3 Bachem Peptide CDMO Services Product and Services
        7.9.4 Bachem Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 Bachem Recent Developments/Updates
        7.9.6 Bachem Competitive Strengths & Weaknesses
    7.10 Merck
        7.10.1 Merck Details
        7.10.2 Merck Major Business
        7.10.3 Merck Peptide CDMO Services Product and Services
        7.10.4 Merck Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 Merck Recent Developments/Updates
        7.10.6 Merck Competitive Strengths & Weaknesses
    7.11 Asymchem
        7.11.1 Asymchem Details
        7.11.2 Asymchem Major Business
        7.11.3 Asymchem Peptide CDMO Services Product and Services
        7.11.4 Asymchem Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Asymchem Recent Developments/Updates
        7.11.6 Asymchem Competitive Strengths & Weaknesses
    7.12 Zhejiang Jiuzhou Pharmaceutical
        7.12.1 Zhejiang Jiuzhou Pharmaceutical Details
        7.12.2 Zhejiang Jiuzhou Pharmaceutical Major Business
        7.12.3 Zhejiang Jiuzhou Pharmaceutical Peptide CDMO Services Product and Services
        7.12.4 Zhejiang Jiuzhou Pharmaceutical Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Developments/Updates
        7.12.6 Zhejiang Jiuzhou Pharmaceutical Competitive Strengths & Weaknesses
    7.13 Sinopep
        7.13.1 Sinopep Details
        7.13.2 Sinopep Major Business
        7.13.3 Sinopep Peptide CDMO Services Product and Services
        7.13.4 Sinopep Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.13.5 Sinopep Recent Developments/Updates
        7.13.6 Sinopep Competitive Strengths & Weaknesses
    7.14 Frontier Biotechnologies
        7.14.1 Frontier Biotechnologies Details
        7.14.2 Frontier Biotechnologies Major Business
        7.14.3 Frontier Biotechnologies Peptide CDMO Services Product and Services
        7.14.4 Frontier Biotechnologies Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.14.5 Frontier Biotechnologies Recent Developments/Updates
        7.14.6 Frontier Biotechnologies Competitive Strengths & Weaknesses
    7.15 JYMed
        7.15.1 JYMed Details
        7.15.2 JYMed Major Business
        7.15.3 JYMed Peptide CDMO Services Product and Services
        7.15.4 JYMed Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.15.5 JYMed Recent Developments/Updates
        7.15.6 JYMed Competitive Strengths & Weaknesses
    7.16 Chengdu Shengnuo Biotechnology
        7.16.1 Chengdu Shengnuo Biotechnology Details
        7.16.2 Chengdu Shengnuo Biotechnology Major Business
        7.16.3 Chengdu Shengnuo Biotechnology Peptide CDMO Services Product and Services
        7.16.4 Chengdu Shengnuo Biotechnology Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.16.5 Chengdu Shengnuo Biotechnology Recent Developments/Updates
        7.16.6 Chengdu Shengnuo Biotechnology Competitive Strengths & Weaknesses
    7.17 Shanghai Soho-Yiming Pharmaceuticals
        7.17.1 Shanghai Soho-Yiming Pharmaceuticals Details
        7.17.2 Shanghai Soho-Yiming Pharmaceuticals Major Business
        7.17.3 Shanghai Soho-Yiming Pharmaceuticals Peptide CDMO Services Product and Services
        7.17.4 Shanghai Soho-Yiming Pharmaceuticals Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.17.5 Shanghai Soho-Yiming Pharmaceuticals Recent Developments/Updates
        7.17.6 Shanghai Soho-Yiming Pharmaceuticals Competitive Strengths & Weaknesses
    7.18 Chinese Peptide Company
        7.18.1 Chinese Peptide Company Details
        7.18.2 Chinese Peptide Company Major Business
        7.18.3 Chinese Peptide Company Peptide CDMO Services Product and Services
        7.18.4 Chinese Peptide Company Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.18.5 Chinese Peptide Company Recent Developments/Updates
        7.18.6 Chinese Peptide Company Competitive Strengths & Weaknesses
    7.19 Ambio Pharmaceuticals
        7.19.1 Ambio Pharmaceuticals Details
        7.19.2 Ambio Pharmaceuticals Major Business
        7.19.3 Ambio Pharmaceuticals Peptide CDMO Services Product and Services
        7.19.4 Ambio Pharmaceuticals Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.19.5 Ambio Pharmaceuticals Recent Developments/Updates
        7.19.6 Ambio Pharmaceuticals Competitive Strengths & Weaknesses
    7.20 Zhejiang Peptites Biotech
        7.20.1 Zhejiang Peptites Biotech Details
        7.20.2 Zhejiang Peptites Biotech Major Business
        7.20.3 Zhejiang Peptites Biotech Peptide CDMO Services Product and Services
        7.20.4 Zhejiang Peptites Biotech Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.20.5 Zhejiang Peptites Biotech Recent Developments/Updates
        7.20.6 Zhejiang Peptites Biotech Competitive Strengths & Weaknesses
    7.21 STA Pharmaceutical
        7.21.1 STA Pharmaceutical Details
        7.21.2 STA Pharmaceutical Major Business
        7.21.3 STA Pharmaceutical Peptide CDMO Services Product and Services
        7.21.4 STA Pharmaceutical Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
        7.21.5 STA Pharmaceutical Recent Developments/Updates
        7.21.6 STA Pharmaceutical Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Peptide CDMO Services Industry Chain
    8.2 Peptide CDMO Services Upstream Analysis
    8.3 Peptide CDMO Services Midstream Analysis
    8.4 Peptide CDMO Services Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Peptide CDMO Services Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Peptide CDMO Services Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Peptide CDMO Services Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Peptide CDMO Services Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Peptide CDMO Services Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Peptide CDMO Services Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Peptide CDMO Services Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Peptide CDMO Services Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Peptide CDMO Services Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Peptide CDMO Services Players in 2022
    Table 12. World Peptide CDMO Services Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Peptide CDMO Services Company Evaluation Quadrant
    Table 14. Head Office of Key Peptide CDMO Services Player
    Table 15. Peptide CDMO Services Market: Company Product Type Footprint
    Table 16. Peptide CDMO Services Market: Company Product Application Footprint
    Table 17. Peptide CDMO Services Mergers & Acquisitions Activity
    Table 18. United States VS China Peptide CDMO Services Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Peptide CDMO Services Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Peptide CDMO Services Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Peptide CDMO Services Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Peptide CDMO Services Revenue Market Share (2018-2023)
    Table 23. China Based Peptide CDMO Services Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Peptide CDMO Services Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Peptide CDMO Services Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Peptide CDMO Services Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Peptide CDMO Services Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Peptide CDMO Services Revenue Market Share (2018-2023)
    Table 29. World Peptide CDMO Services Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Peptide CDMO Services Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Peptide CDMO Services Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Peptide CDMO Services Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Peptide CDMO Services Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Peptide CDMO Services Market Size by Application (2024-2029) & (USD Million)
    Table 35. Incyte Basic Information, Area Served and Competitors
    Table 36. Incyte Major Business
    Table 37. Incyte Peptide CDMO Services Product and Services
    Table 38. Incyte Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Incyte Recent Developments/Updates
    Table 40. Incyte Competitive Strengths & Weaknesses
    Table 41. Gliead Basic Information, Area Served and Competitors
    Table 42. Gliead Major Business
    Table 43. Gliead Peptide CDMO Services Product and Services
    Table 44. Gliead Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Gliead Recent Developments/Updates
    Table 46. Gliead Competitive Strengths & Weaknesses
    Table 47. Boehringer Ingelheim Basic Information, Area Served and Competitors
    Table 48. Boehringer Ingelheim Major Business
    Table 49. Boehringer Ingelheim Peptide CDMO Services Product and Services
    Table 50. Boehringer Ingelheim Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Boehringer Ingelheim Recent Developments/Updates
    Table 52. Boehringer Ingelheim Competitive Strengths & Weaknesses
    Table 53. Vertex Basic Information, Area Served and Competitors
    Table 54. Vertex Major Business
    Table 55. Vertex Peptide CDMO Services Product and Services
    Table 56. Vertex Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Vertex Recent Developments/Updates
    Table 58. Vertex Competitive Strengths & Weaknesses
    Table 59. Mirati Therapeutics Basic Information, Area Served and Competitors
    Table 60. Mirati Therapeutics Major Business
    Table 61. Mirati Therapeutics Peptide CDMO Services Product and Services
    Table 62. Mirati Therapeutics Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Mirati Therapeutics Recent Developments/Updates
    Table 64. Mirati Therapeutics Competitive Strengths & Weaknesses
    Table 65. AMPAC Basic Information, Area Served and Competitors
    Table 66. AMPAC Major Business
    Table 67. AMPAC Peptide CDMO Services Product and Services
    Table 68. AMPAC Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. AMPAC Recent Developments/Updates
    Table 70. AMPAC Competitive Strengths & Weaknesses
    Table 71. Pfizer Basic Information, Area Served and Competitors
    Table 72. Pfizer Major Business
    Table 73. Pfizer Peptide CDMO Services Product and Services
    Table 74. Pfizer Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. Pfizer Recent Developments/Updates
    Table 76. Pfizer Competitive Strengths & Weaknesses
    Table 77. Polypeptide Basic Information, Area Served and Competitors
    Table 78. Polypeptide Major Business
    Table 79. Polypeptide Peptide CDMO Services Product and Services
    Table 80. Polypeptide Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Polypeptide Recent Developments/Updates
    Table 82. Polypeptide Competitive Strengths & Weaknesses
    Table 83. Bachem Basic Information, Area Served and Competitors
    Table 84. Bachem Major Business
    Table 85. Bachem Peptide CDMO Services Product and Services
    Table 86. Bachem Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. Bachem Recent Developments/Updates
    Table 88. Bachem Competitive Strengths & Weaknesses
    Table 89. Merck Basic Information, Area Served and Competitors
    Table 90. Merck Major Business
    Table 91. Merck Peptide CDMO Services Product and Services
    Table 92. Merck Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. Merck Recent Developments/Updates
    Table 94. Merck Competitive Strengths & Weaknesses
    Table 95. Asymchem Basic Information, Area Served and Competitors
    Table 96. Asymchem Major Business
    Table 97. Asymchem Peptide CDMO Services Product and Services
    Table 98. Asymchem Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 99. Asymchem Recent Developments/Updates
    Table 100. Asymchem Competitive Strengths & Weaknesses
    Table 101. Zhejiang Jiuzhou Pharmaceutical Basic Information, Area Served and Competitors
    Table 102. Zhejiang Jiuzhou Pharmaceutical Major Business
    Table 103. Zhejiang Jiuzhou Pharmaceutical Peptide CDMO Services Product and Services
    Table 104. Zhejiang Jiuzhou Pharmaceutical Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 105. Zhejiang Jiuzhou Pharmaceutical Recent Developments/Updates
    Table 106. Zhejiang Jiuzhou Pharmaceutical Competitive Strengths & Weaknesses
    Table 107. Sinopep Basic Information, Area Served and Competitors
    Table 108. Sinopep Major Business
    Table 109. Sinopep Peptide CDMO Services Product and Services
    Table 110. Sinopep Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 111. Sinopep Recent Developments/Updates
    Table 112. Sinopep Competitive Strengths & Weaknesses
    Table 113. Frontier Biotechnologies Basic Information, Area Served and Competitors
    Table 114. Frontier Biotechnologies Major Business
    Table 115. Frontier Biotechnologies Peptide CDMO Services Product and Services
    Table 116. Frontier Biotechnologies Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 117. Frontier Biotechnologies Recent Developments/Updates
    Table 118. Frontier Biotechnologies Competitive Strengths & Weaknesses
    Table 119. JYMed Basic Information, Area Served and Competitors
    Table 120. JYMed Major Business
    Table 121. JYMed Peptide CDMO Services Product and Services
    Table 122. JYMed Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 123. JYMed Recent Developments/Updates
    Table 124. JYMed Competitive Strengths & Weaknesses
    Table 125. Chengdu Shengnuo Biotechnology Basic Information, Area Served and Competitors
    Table 126. Chengdu Shengnuo Biotechnology Major Business
    Table 127. Chengdu Shengnuo Biotechnology Peptide CDMO Services Product and Services
    Table 128. Chengdu Shengnuo Biotechnology Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 129. Chengdu Shengnuo Biotechnology Recent Developments/Updates
    Table 130. Chengdu Shengnuo Biotechnology Competitive Strengths & Weaknesses
    Table 131. Shanghai Soho-Yiming Pharmaceuticals Basic Information, Area Served and Competitors
    Table 132. Shanghai Soho-Yiming Pharmaceuticals Major Business
    Table 133. Shanghai Soho-Yiming Pharmaceuticals Peptide CDMO Services Product and Services
    Table 134. Shanghai Soho-Yiming Pharmaceuticals Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 135. Shanghai Soho-Yiming Pharmaceuticals Recent Developments/Updates
    Table 136. Shanghai Soho-Yiming Pharmaceuticals Competitive Strengths & Weaknesses
    Table 137. Chinese Peptide Company Basic Information, Area Served and Competitors
    Table 138. Chinese Peptide Company Major Business
    Table 139. Chinese Peptide Company Peptide CDMO Services Product and Services
    Table 140. Chinese Peptide Company Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 141. Chinese Peptide Company Recent Developments/Updates
    Table 142. Chinese Peptide Company Competitive Strengths & Weaknesses
    Table 143. Ambio Pharmaceuticals Basic Information, Area Served and Competitors
    Table 144. Ambio Pharmaceuticals Major Business
    Table 145. Ambio Pharmaceuticals Peptide CDMO Services Product and Services
    Table 146. Ambio Pharmaceuticals Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 147. Ambio Pharmaceuticals Recent Developments/Updates
    Table 148. Ambio Pharmaceuticals Competitive Strengths & Weaknesses
    Table 149. Zhejiang Peptites Biotech Basic Information, Area Served and Competitors
    Table 150. Zhejiang Peptites Biotech Major Business
    Table 151. Zhejiang Peptites Biotech Peptide CDMO Services Product and Services
    Table 152. Zhejiang Peptites Biotech Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 153. Zhejiang Peptites Biotech Recent Developments/Updates
    Table 154. STA Pharmaceutical Basic Information, Area Served and Competitors
    Table 155. STA Pharmaceutical Major Business
    Table 156. STA Pharmaceutical Peptide CDMO Services Product and Services
    Table 157. STA Pharmaceutical Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 158. Global Key Players of Peptide CDMO Services Upstream (Raw Materials)
    Table 159. Peptide CDMO Services Typical Customers
List of Figure
    Figure 1. Peptide CDMO Services Picture
    Figure 2. World Peptide CDMO Services Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Peptide CDMO Services Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Peptide CDMO Services Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Peptide CDMO Services Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Peptide CDMO Services Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Peptide CDMO Services Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Peptide CDMO Services Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Peptide CDMO Services Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Peptide CDMO Services Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Peptide CDMO Services Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Peptide CDMO Services Revenue (2018-2029) & (USD Million)
    Figure 13. Peptide CDMO Services Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Peptide CDMO Services Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Peptide CDMO Services Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Peptide CDMO Services Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Peptide CDMO Services Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Peptide CDMO Services Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Peptide CDMO Services Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Peptide CDMO Services Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Peptide CDMO Services Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Peptide CDMO Services Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Peptide CDMO Services by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide CDMO Services Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide CDMO Services Markets in 2022
    Figure 27. United States VS China: Peptide CDMO Services Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Peptide CDMO Services Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Peptide CDMO Services Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Peptide CDMO Services Market Size Market Share by Type in 2022
    Figure 31. Small Molecule CDMO
    Figure 32. Macro-molecular CDMO
    Figure 33. World Peptide CDMO Services Market Size Market Share by Type (2018-2029)
    Figure 34. World Peptide CDMO Services Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 35. World Peptide CDMO Services Market Size Market Share by Application in 2022
    Figure 36. Clinical Treatment
    Figure 37. Medical Research
    Figure 38. Commercial Production
    Figure 39. Peptide CDMO Services Industrial Chain
    Figure 40. Methodology
    Figure 41. Research Process and Data Source

Companies Mentioned

Incyte
Gliead
Boehringer Ingelheim
Vertex
Mirati Therapeutics
AMPAC
Pfizer
Polypeptide
Bachem
Merck
Asymchem
Zhejiang Jiuzhou Pharmaceutical
Sinopep
Frontier Biotechnologies
JYMed
Chengdu Shengnuo Biotechnology
Shanghai Soho-Yiming Pharmaceuticals
Chinese Peptide Company
Ambio Pharmaceuticals
Zhejiang Peptites Biotech
STA Pharmaceutical